ADVENTRX Announces Appointment of Chief Financial Officer

          ADVENTRX Announces Appointment of Chief Financial Officer

PR Newswire

SAN DIEGO, Jan. 4, 2013

SAN DIEGO, Jan. 4, 2013 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE
MKT: ANX) today announced the appointment of Brandi L. Roberts to Chief
Financial Officer and Senior Vice President, effective January 2, 2013. She
had served as the Company's vice president, finance since March 2011.
Ms.Roberts has over 17 years of public accounting and finance experience,
including 14 years at publicly-traded pharmaceutical and life science

"Brandi's prior experience at publicly-traded, clinical and commercial stage
companies, combined with her business and financial acumen, enable her to
provide important insight and direction at this important stage for our
company," stated Brian M. Culley, Chief Executive Officer of ADVENTRX. "With
the initiation of our phase 3 trial of ANX‑188 in sickle cell disease and as
we solidify plans for development of ANX-188 in an indication outside of
sickle cell disease, Brandi will continue to be a valuable member of our
management team."

Prior to joining ADVENTRX, from January 2009 to March 2011, Ms. Roberts served
as vice president, accounting and corporate controller of Alphatec Spine,
Inc., the wholly-owned operating subsidiary of Alphatec Holdings, Inc., a
medical technology company with annual revenue in excess of $170 million
listed on the NASDAQ Global Select Market. Ms. Roberts' experience also
includes seven years at Pfizer's laboratories in La Jolla, California
(formerly Agouron), most recently as director, finance, and three years with
the public accounting firm of PricewaterhouseCoopers LLP. She is a certified
public accountant with the State of California. Ms. Roberts currently serves
as co-chair of the San Diego Chapter of the Association of Bioscience
Financial Officers.

About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical company developing proprietary
product candidates to treat various diseases and conditions. The Company's
lead product candidate, ANX-188, has potential to reduce ischemic tissue
injury and end-organ damage by restoring microvascular function, which is
compromised in a wide range of serious and life-threatening diseases and
conditions. The Company initially is developing ANX-188 as a treatment for
complications arising from sickle cell disease. More information can be found
on the Company's web site at

Forward Looking Statements
ADVENTRX cautions you that statements included in this press release that are
not a description of historical facts are forward-looking statements that are
based on ADVENTRX's current expectations and assumptions. Such forward-looking
statements include, but are not limited to, statements regarding the planned
phase 3 clinical study of ANX-188, including the timing of its initiation, and
the development of ANX-188 outside of sickle cell disease. Among the factors
that could cause or contribute to material differences between ADVENTRX's
actual results and those indicated from the forward-looking statements are
risks and uncertainties inherent in ADVENTRX's business, including, but not
limited to: the potential for delays in the commencement or completion of
planned clinical studies, including the phase 3 study of ANX-188 in sickle
cell disease, including as a result of difficulties in completing
manufacturing process development activities, manufacturing clinical trial
material, meeting applicable regulatory requirements for clinical trial
material, meeting applicable requirements of institutional review boards
overseeing clinical study sites, negotiating agreements with potential
clinical study sites, enrolling study subjects or being subject to a "clinical
hold"; the risk that the rate of enrollment in the planned phase 3 study of
ANX-188 is slower than was anticipated prior to the study's initiation; the
impact of missing or imputed data on the treatment effect observed in the
prior phase 3 study of ANX-188 in sickle cell disease; the risk of suspension
or termination of a clinical study, including due to lack of adequate funding
or a "clinical hold"; ADVENTRX's reliance on contract research organizations
(CROs) and other third parties to assist in the conduct of important aspects
of its clinical studies, and that such third parties may fail to perform as
expected; the risk that planned clinical studies are not successfully executed
and/or do not successfully demonstrate the safety or efficacy of the
investigational drug; the risk that, even if clinical studies are successful,
the FDA determines they are not sufficient to support a new drug application;
the risk that even if clinical studies of an investigational drug in one
indication are successful, clinical studies of the same investigational drug
in another indication may not be successful; ADVENTRX's ability to obtain
additional funding on a timely basis or on acceptable terms, or at all; the
potential for ADVENTRX to delay, reduce or discontinue current and/or planned
development activities, including clinical studies, partner its product
candidates at inopportune times or pursue less expensive but higher-risk
development paths if it is unable to raise sufficient additional capital as
needed; the risk that the FDA does not grant marketing approval of ADVENTRX's
product candidates, including ANX-188, on a timely basis, or at all; and other
risks and uncertainties more fully described in ADVENTRX's press releases and
periodic filings with the Securities and Exchange Commission. ADVENTRX's
public filings with the Securities and Exchange Commission are available at

You are cautioned not to place undue reliance on forward-looking statements,
which speak only as of the date when made. ADVENTRX does not intend to revise
or update any forward-looking statement set forth in this press release to
reflect events or circumstances arising after the date hereof, except as may
be required by law.


SOURCE ADVENTRX Pharmaceuticals, Inc.

Contact: ADVENTRX Pharmaceuticals: Ioana C. Hone (,
+1-858-552-0866 Ext. 303
Press spacebar to pause and continue. Press esc to stop.